Table 2

Impact of Screening on Cardiovascular Morbidity and the Prescription of Cardioprotective Drugs in the ADDITION-Cambridge Trial at 7-year Follow-up

Screening GroupNo-screening Control GroupOdds Ratio (95%CI)a
Cardiovascular morbidity, n (%)
Self-reported cardiovascular eventsb142 (12.4)67 (13.5)0.90 (0.71–1.15)
Self-reported hypertension809 (60.9)352 (63.4)0.90 (0.75–1.08)
Self-reported dyslipidemia502 (41.2)254 (48.3)0.75 (0.64–0.88)
Prescribed medication, n (%)
Antihypertensive drugs853 (72.5)369 (74.7)0.89 (0.73–1.10)
ACE inhibitors546 (46.4)244 (49.4)0.89 (0.75–1.06)
Lipid lowering drugs507 (43.1)244 (49.4)0.78 (0.63–0.95)
Antiplatelet drugs335 (28.5)185 (37.5)0.67 (0.53–0.83)
Glucose lowering drugs97 (8.3)48 (9.7)0.84 (0.57–1.21)

  • ACE = angiotensin-converting enzyme.

  • ↵a Accounting for clustering by general practice.

  • ↵b A cardiovascular event was defined as myocardial infarction or stroke.